Peramivir: Evidence to Support the Use of the First Approved Intravenous Therapy for Influenza
Authors:
- 13 August 2015
- journal article
- Published by Taylor & Francis in Future Virology
- Vol. 10 (8) , 937-948
Abstract
Peramivir, an intravenous neuraminidase inhibitor, was first available in clinical practice during the 2009 A/H1N1 pandemic under an Emergency Use Authorization by the US FDA. As the lone intravenous neuraminidase inhibitor available and with a novel structure compared with the available neuraminidase inhibitors, it was offered as an alternative to patients not responding to existing therapy or without enteric access. Since the expiration of the Emergency Use Authorization, peramivir has undergone multiple clinical trials for the treatment of both uncomplicated influenza infection in the ambulatory setting and complicated influenza infection in the hospitalized setting. With the recent FDA approval of single-dose therapy for uncomplicated influenza infection, we will review the preclinical and clinical data, to date, on peramivir.Keywords
Funding Information
- Northwestern University
- Anolinx
- BioCryst
- Chimerix
- Gilead
- GlaxoSmithKlein
- Viropharma
This publication has 66 references indexed in Scilit:
- Efficacy, Safety, and Pharmacokinetics of Intravenous Peramivir in Children with 2009 Pandemic H1N1 Influenza A Virus InfectionAntimicrobial Agents and Chemotherapy, 2012
- Phase III Randomized, Double-Blind Study Comparing Single-Dose Intravenous Peramivir with Oral Oseltamivir in Patients with Seasonal Influenza Virus InfectionAntimicrobial Agents and Chemotherapy, 2011
- Postpartum Pharmacokinetics of Peramivir in the Treatment of 2009 H1N1 InfluenzaObstetrics & Gynecology, 2011
- Intravenous Peramivir for Treatment of Influenza A and B Virus Infection in High-Risk PatientsAntimicrobial Agents and Chemotherapy, 2011
- Systematic review of influenza resistance to the neuraminidase inhibitorsBMC Infectious Diseases, 2011
- Clinical Experience in Adults and Children Treated with Intravenous Peramivir for 2009 Influenza A (H1N1) Under an Emergency IND Program in the United StatesClinical Infectious Diseases, 2011
- Efficacy and Safety of Intravenous Peramivir for Treatment of Seasonal Influenza Virus InfectionAntimicrobial Agents and Chemotherapy, 2010
- Critically Ill Patients With 2009 Influenza A(H1N1) Infection in CanadaJAMA, 2009
- Emergence of a Novel Swine-Origin Influenza A (H1N1) Virus in HumansNew England Journal of Medicine, 2009
- Influenza-Associated Hospitalizations in the United StatesJAMA, 2004